Irinotecan and gemcitabine in patients with solid tumors: phase I trial.

Oncology (Williston Park, N.Y.)

Volumn 16, Issue 5 Suppl 5, 2002, Pages 19-24

  Rocha Lima, Caio Max ^a   Leong, Swan Swan ^a   Sherman, Carol A ^a   Perkel, Joshua A ^a   Putman, Terri ^a   Safa, Ahmad R ^a   Green, Mark R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; IRINOTECAN;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DIARRHEA; HEMATOLOGIC DISEASE; HUMAN; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEOPLASM; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DIARRHEA; HEMATOLOGIC DISEASES; HUMANS; MAXIMUM TOLERATED DOSE; NAUSEA; NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; PANCREATIC NEOPLASMS; VOMITING;

EID: 0036560251     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)